Genentech’s Vabysmo Shows Long-Term Benefits in Wet AMD
Genentech Presents New Long-Term Data for Vabysmo in Wet AMD and PCV at Euretina Congress 2025 Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), has announced…
Read MoreGenentech’s Vabysmo Shows Long-Term Benefits in Wet AMD
WHO Expands Essential Medicines List with Cancer, Diabetes Drugs
WHO Expands Essential Medicines Lists to Include Landmark Treatments for Cancer, Diabetes, and Other Major Disease The World Health Organization (WHO) has announced a major update to its Model Lists…
Roche’s Vabysmo Shows Strong Results in Wet AMD
Roche’s Vabysmo Reinforces Long-Term Benefits in Wet Age-Related Macular Degeneration and Shows Strong Gains in Polypoidal Choroidal Vasculopathy Paris, France – At the 25th annual Euretina Congress, one of the…
SCIEX BioPhase 8800 Debuts Native Fluorescence Detection for Protein CE
SCIEX Expands BioPhase 8800 Capabilities with Native Fluorescence Detection to Advance Protein-Based CE Assays At the 2025 CE Pharm conference, SCIEX, a global leader in life science analytical technologies, announced…
Octave Bioscience Secures $35M in Series C Funding to Drive Commercial Growth
Octave Bioscience Secures $35.6 Million Series C Financing and $15.5 Million Loan to Accelerate Growth and Advance Precision Care in Neurology Octave Bioscience, Inc., a commercial-stage precision care company dedicated…
Gilead, PEPFAR Partner to Expand Twice-Yearly HIV Prevention
Gilead Partners With PEPFAR and Global Fund to Deliver Twice-Yearly Lenacapavir for HIV Prevention Across Low- and Lower-Middle-Income Countries Gilead Sciences, Inc. (Nasdaq: GILD) has announced a major new global…
MRM Health Secures €55M Series B for Microbiome Therapeutics
MRM Health Secures €55 Million Series B Financing to Accelerate Development of Best-in-Class Microbiome-Based Biotherapeutics MRM Health NV, a pioneering clinical-stage biopharmaceutical company developing transformative microbiome-based therapeutics, announced the successful…
MEDIPAL and JCR Partner on Global Licensing for GM2 Therapy JR-479
MEDIPAL Holdings and JCR Pharmaceuticals Expand Rare Disease Collaboration with Global Licensing and Japan Co-Development Agreement for JR-479, a Novel Investigational Therapy for GM2 Gangliosidosis In a significant advancement for…
Texas Expands Access to Relief with House Bill 46 and an Enhanced Medical Cannabis Program
Texas Expands Medical Cannabis Access with House Bill 46: A New Era for Patient For thousands of Texans who live each day with the burden of chronic pain, traumatic brain…
Purdue Pharma Expands Low-Cost OUD Treatment to Prisons
Purdue Pharma Expands Access to Low-Cost Opioid Use Disorder Treatment in U.S. Correctional Facilities On the occasion of International Overdose Awareness Day, Purdue Pharma L.P. (“Purdue”) announced an expansion of…
Neurotech Welcomes Dr. Peter J. McDonnell to Its Board of Directors
Neurotech Pharmaceuticals Strengthens Leadership with Appointment of Dr. Peter J. McDonnell to Board of Directors Neurotech Pharmaceuticals, Inc., a privately held biotechnology company pioneering transformative therapies for chronic eye diseases,…
Enlaza and Vertex Partner on War-Lock Conjugates and T-Cell Engagers
Enlaza Therapeutics and Vertex Pharmaceuticals Forge Multi-Billion-Dollar Collaboration to Advance Next-Generation Covalent Biologics in Autoimmune Diseases and Conditioning Therapies Enlaza Therapeutics (“Enlaza” or the “Company”), a pioneering biotechnology firm and…